Trial Profile
A Phase 1b Dose-escalation Study Evaluating the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Subjects With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs GS 9901 (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 16 Oct 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov
- 20 May 2015 Planned End Date changed from 1 Oct 2016 to 1 Nov 2017 as per ClinicalTrials.gov record.
- 20 May 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2017 as per ClinicalTrials.gov record.